Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clene Inc
(NQ:
CLNN
)
0.4251
+0.0533 (+14.34%)
Streaming Delayed Price
Updated: 3:38 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clene Inc
< Previous
1
2
3
Next >
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
February 13, 2024
Via
Investor Brand Network
New MRI Procedure Eases Multiple Sclerosis Diagnosis
February 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
February 06, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
February 06, 2024
Via
Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial.
Via
TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
February 02, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
January 30, 2024
Via
Investor Brand Network
Researchers Propose New Way to Classify Parkinson’s Disease
January 29, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
January 22, 2024
Via
Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
January 17, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
January 08, 2024
Via
Investor Brand Network
New Study Highlights Role of Mitochondria in Connecting Cancer to Dietary Fat
January 04, 2024
Via
Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials
January 02, 2024
Via
Investor Brand Network
Finnish Study Suggests Exercise Plays Smaller Role in Longevity
December 21, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial, Provides Update on ALS Clinical Development Meeting with FDA
December 21, 2023
Via
Investor Brand Network
Exposures
Product Safety
How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
December 18, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
December 14, 2023
Via
Investor Brand Network
Stem Cell Therapy Shows Promise in Halting Progression of Cognitive Decline in MS Patients
December 11, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
December 08, 2023
Via
Investor Brand Network
The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
December 08, 2023
Via
Investor Brand Network
Study Suggests Parkinson’s Could Be Linked to Onset of Stroke, Heart Disease
November 29, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
November 22, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
November 16, 2023
Via
Investor Brand Network
Blood Test Could Detect Worsening MS Symptoms in Patients
November 15, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
November 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
November 07, 2023
Via
Investor Brand Network
Exposures
Product Safety
Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset
November 03, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
October 30, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
October 25, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
October 17, 2023
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.